Doing Well By Doing Good: FDA's Orphan Product Head Makes His Case to Pharma
This article was originally published in RPM Report
Executive Summary
Tim Coté has been a tireless advocate for greater involvement by Big Pharma in orphan drug research since taking over as head of FDA's Orphan Products Office two years ago. We talked to him about the response he's heard so far.
You may also be interested in...
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Hit hard by late stage pipeline failures and the regulatory and reimbursement challenges of traditional primary care products, Big Pharmas are taking renewed interest in drugs for orphan diseases, where high unmet medical need offers the promise of premium pricing and there's potential to grow the market via approval in multiple indications.
A Rare Opportunity? NIH Program For Rare Diseases May Have Big Payoff For Drug Development
NIH Director Francis Collins is very excited about a $24 million program to de-risk small molecule treatments for rare disorders. You should be too.